Hexarelin
Synthetic hexapeptide of the growth-hormone secretagogue (GHRP) family. In the 1990s investigated as an acromegaly diagnostic and for GH deficiency. Not an approved medicine.
Mechanism of action
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence at a glance
What the studies show
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.9 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Routes of administration in the literature
Safer use & risks
Known adverse events from studies
Interactions & combinations
Risks & hygiene aspects in the literature
WADA status
Anecdotal observations
Legal status by country
Reconstitution calculator
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Cofactors
These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
Study register
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide
Pharmacokinetics and pharmacodynamics of hexarelin in humans
Cardiovascular effects of hexarelin and other GH secretagogues
Cardiovascular activity of hexarelin in the rat: GHS-R independent mechanisms
Sources & method
Get new studies on Hexarelin
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy